MAximising Therapeutic Utility in Rheumatoid Arthritis
Toggle navigation
Home
Our Research
TranSMART
About Us
About Us
Academic and Industry Partners
News and publications
Patient/Public Involvment
What is MATURA?
EPIC-RA – Patient Survey
Get Involved MPAG
Highlights and News
Jargon buster
Synovial biopsy: patient interview
Contact Us
Highlights and News
Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue - Nature
Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue
Nature
Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition - Frontiers
Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition
Frontiers
Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts - The Lancet
Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts
The Lancet
Clinical implications of synovial tissue phenotypes in rheumatoid arthritis - Frontiers
Clinical implications of synovial tissue phenotypes in rheumatoid arthritis
Frontiers
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial - Nature
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
Nature
(PDF) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - researchgate.net
(PDF) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
researchgate.net
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials - The Lancet
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
The Lancet
Oral Presentation Abstracts - 2024 - International Journal of Rheumatic Diseases - Wiley Online Library
Oral Presentation Abstracts - 2024 - International Journal of Rheumatic Diseases
Wiley Online Library
Are innovation and new technologies in precision medicine paving a new era in patients centric care? - Journal of Translational Medicine
Are innovation and new technologies in precision medicine paving a new era in patients centric care?
Journal of Translational Medicine
Clinical Applications of Synovial Biopsy - Frontiers
Clinical Applications of Synovial Biopsy
Frontiers
Rheumatoid arthritis - The Lancet
Rheumatoid arthritis
The Lancet
Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics - Nature
Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics
Nature
Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy - Frontiers
Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy
Frontiers
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial - The Lancet
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial
The Lancet
Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis - Nature
Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis
Nature
Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis - Frontiers
Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis
Frontiers
Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis - Nature
Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
Nature
Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes - Frontiers
Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes
Frontiers
A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients - Frontiers
A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients
Frontiers
Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs - Frontiers
Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs
Frontiers
Table 1 Identification of poor prognostic factors in randomized trials... - researchgate.net
Table 1 Identification of poor prognostic factors in randomized trials...
researchgate.net
Related
What is MATURA?
EPIC-RA – Patient Survey
Get Involved MPAG
Highlights and News
The MATURA consortium
includes academic groups and industry partners working together to identify and test biomarkers
predictive of response to biological therapy in patients with rheumatoid arthritis
Home
| Copyright © Experimental Medicine & Rheumatology Department, Queen Mary University London, 2015 - 2025 |
Sitemap